Artios Pharma Expands US Management Team with the Appointment of Abid Ansari as Chief Economic Officer

CAMBRIDGE, England and NEW YORK, Jan. 12, 2021 /PRNewswire/ — Artios Pharma Restricted (“Artios”), a foremost DNA Harm Response (DDR) corporation developing a broad pipeline of precision medications for the procedure of cancer, announces the appointment of Abid Ansari as Main Money Officer (CFO).

Abid will direct the company’s monetary, investor relations, and general public relations operations, where by he delivers a variety of US economical expertise to Artios, which include a qualifications with global public corporations in corporate finance, organization improvement, licensing, and trader relations. He joins Tania Dimitrova, Chief Organization Officer, in the company’s US subsidiary set up due to the fact 2019.

Abid has 18 decades of finance expertise in everyday living science corporations. Prior to joining Artios Pharma, he most not too long ago served as CFO of Precision BioSciences (NASDAQ: DTIL), a upcoming generation genome enhancing firm.  There he served the business increase over $300M in cash, like a $146M IPO and $110M Collection B. Abid also labored at GlaxoSmithKline for five many years in offer finance and portfolio management roles and at MedImmune LLC in business and funds finance roles.

Abid Ansari holds a Bachelor of Science degree in chemical engineering and a Learn of Business enterprise Administration, both equally from Purdue College.  He is also a CPA. 

Andrew Muncey, Artios’ British isles-primarily based CFO given that 2016 turns into Chief Operating Officer (COO), in which he will be liable for the lawful, corporation secretarial, HR, IT, amenities and operational capabilities of the firm, including guiding the company in its transition from a preclinical firm to a fully-fledged scientific DDR corporation. Andrew has in excess of 20 many years of management experience in biotechnology and a qualifications in investment banking, money markets and company finance.

Niall Martin, Main Government Officer of Artios, stated: “I am delighted to welcome Abid to Artios at this remarkable time for the firm, as we glimpse to accelerate development in our pipeline and shift our very first prospect into medical enhancement. Abid is a crucial addition to our Govt Administration staff and strengthens our presence in the US. He will participate in an instrumental function in guiding Artios through its long term funding levels. I also would like to thank Andrew for his outstanding get the job done about the previous 5 many years as CFO and glimpse ahead to functioning with him in his new position as COO.”

Abid Ansari, Main Economic Officer of Artios, stated: “Artios is a entire world leader in the area of DNA hurt reaction. This is an primarily enjoyable time to be part of as the organization tends to make the changeover to an early-phase medical oncology corporation. I am enthusiastic about doing work with Niall and the group to carry Artios’ transformational science to individuals as precision oncology medicines.”

About Artios Pharma Restricted

Artios is a foremost DNA Harm Response (DDR) business concentrated on developing 1st-in-course treatment options for cancer.  The Business is led by an knowledgeable management workforce with planet class scientific capabilities and verified skills in DDR drug discovery, such as the identification and improvement of the PARP inhibitor olaparib.  It has a special partnership with Most cancers Analysis United kingdom (CRUK), and collaborations with top DNA fix researchers around the globe, these types of as The Institute of Most cancers Study (ICR), London, the Netherlands Most cancers Institute (NKI) and The Francis Crick Institute, London. Artios is constructing a pipeline of up coming-generation DDR programmes to target really hard to take care of cancers which will shift into Phase 1 medical experiments in 2021. These include ATR inhibitor Art0380 for dealing with DDR defective tumours and the very first-in-course Pol theta inhibitor Artwork4215 for mono therapy and blend treatments. In December 2020, Artios entered into a worldwide three-yr strategic analysis collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medications targeting nucleases.  Artios is backed by blue chip investors which include: AbbVie Ventures, Andera Associates, Arix Bioscience plc, IP Team plc, Existence Science Companions (LSP), M Ventures, Novartis Enterprise Fund (NVF), Pfizer Ventures and SV Wellness Buyers. Artios is dependent at the Babraham Exploration Campus in Cambridge, United kingdom, with an business office in New York Town, United states of america. For more info: www.artiospharma.com

Resource Artios